RT Journal Article
SR Electronic
T1 Identification of Potential Blood-based Biomarkers for Multiple Sclerosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.08.22278573
DO 10.1101/2022.08.08.22278573
A1 Adrija Kundu
YR 2022
UL http://medrxiv.org/content/early/2022/08/10/2022.08.08.22278573.abstract
AB Multiple Sclerosis (MS) is a disease affecting millions of people worldwide caused by an abnormal immune response that deteriorates the myelin sheath encapsulating neurons, drastically impairing neural communication. Currently, no tests can guarantee the diagnosis of MS until symptoms become severe. Early-stage diagnosis for MS is beneficial as it allows for an early start to treatment that slows its progression. This project aimed to analyze data from gene expression studies and identify commonly differentially expressed genes (DEGs) in the blood of MS patients. 183 overexpressed DEGs were identified and a diagram depicting protein interactions was generated with STRINGDB. Cytoscape was used to analyze interactions and recognize Hub genes. Further analysis on PANTHER showed that the biological processes of “tRNA aminoacylation for protein translation” and “mitochondrial translational elongation” were enriched in the upregulated DEGs. Furthermore, processes directly connected to the immune system such as the “Fc receptor signaling pathway” and “antigen processing and presentation of peptide antigen” were overrepresented. The identified Hub genes RPS27A, NSA2, RPS15A, and POLR2C are potential biomarkers for MS and warrant further study. Overall, this study could provide greater insight into the molecular pathways of MS and evidence to support which genes are overexpressed in MS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17048 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21942 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE23832I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17048 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21942 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE23832